Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Takayama, Tetsuro ^a   Ebinuma, Hirotoshi ^a   Tada, Shinichiro ^a   Yamagishi, Yoshiyuki ^a   Wakabayashi, Kanji ^a   Ojiro, Keisuke ^a   Kanai, Takanori ^a   Saito, Hidetsugu ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ACCURACY; ADULT; AGE; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CREATININE BLOOD LEVEL; DATA ANALYSIS; DEMOGRAPHY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENDER; HEPATITIS C; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONLINEAR SYSTEM; OUTCOME ASSESSMENT; PREDICTION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; REPRODUCIBILITY; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEURAL NETWORKS (COMPUTER); POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 82555168483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027223     Document Type: Article

References (42)

1. Strader DB, Wright T, Thomas DL, Seeff LB, (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171.
2. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, et al. (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125: 634-639.
3. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, et al. (1996) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25: 591-598.
4. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, et al. (1994) Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 32: 884-892.
5. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, et al. (1995) Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 122: 161-168.
6. Takada N, Takase S, Takada A, Date T, (1993) Differences in the hepatitis C virus genotypes in different countries. J Hepatol 17: 277-283.
7. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086-1097.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
9. Zeuzem S, (2004) Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140: 370-381.
10. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993-999.
11. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, et al. (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971-981.
12. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131: 451-460.
13. Nakamura M, Saito H, Ikeda M, Tada S, Kumagai N, et al. (2008) Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. J Med Virol 80: 632-639.
14. Saito H, Ebinuma H, Satoh I, Miyaguchi S, Tada S, et al. (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7: 64-74.
15. Saito H, Tada S, Wakabayashi K, Nakamoto N, Takahashi M, et al. (2002) The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C. J Interferon Cytokine Res 22: 693-700.
16. Grossi E, Buscema M, (2007) Introduction to artificial neural networks. Eur J Gastroenterol Hepatol 19: 1046-1054.
17. Takayama K, Fujikawa M, Obata Y, Morishita M, (2003) Neural network based optimization of drug formulations. Adv Drug Deliv Rev 55: 1217-1231.
18. Baxt WG, (1995) Application of artificial neural networks to clinical medicine. Lancet 346: 1135-1138.
19. Cross SS, Harrison RF, Kennedy RL, (1995) Introduction to neural networks. Lancet 346: 1075-1079.
20. Grossi E, Mancini A, Buscema M, (2007) International experience on the use of artificial neural networks in gastroenterology. Dig Liver Dis 39: 278-285.
21. Pace F, Savarino V, (2007) The use of artificial neural network in gastroenterology: the experience of the first 10 years. Eur J Gastroenterol Hepatol 19: 1043-1045.
22. Haydon GH, Flegg PJ, Blair CS, Brettle RP, Burns SM, et al. (1998) The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 10: 485-489.
23. Maiellaro PA, Cozzolongo R, Marino P, (2004) Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. Curr Pharm Des 10: 2101-2109.
24. Das A, Wong RC, (2007) Prediction of outcome in acute lower gastrointestinal hemorrhage: role of artificial neural network. Eur J Gastroenterol Hepatol 19: 1064-1069.
25. Das A, Ben-Menachem T, Cooper GS, Chak A, Sivak MV Jr, et al. (2003) Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet 362: 1261-1266.
26. Haydon GH, Jalan R, Ala-Korpela M, Hiltunen Y, Hanley J, et al. (1998) Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. J Viral Hepat 5: 255-264.
27. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
28. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, et al. (2007) Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79: 1686-1695.
29. Backus LI, Boothroyd DB, Phillips BR, Mole LA, (2007) Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46: 37-47.
30. Takayama K, Morva A, Fujikawa M, Hattori Y, Obata Y, et al. (2000) Formula optimization of theophylline controlled-release tablet based on artificial neural networks. J Control Release 68: 175-186.
31. Yamamura S, (2003) Clinical application of artificial neural network (ANN) modelling to predict pharmacokinetic parameters of severely ill patients. Adv Drug Deliv Rev 55: 1233-1251.
32. Baxt WG, (1991) Use of an artificial neural network for the diagnosis of myocardial infarction. Ann Intern Med 115: 843-848.
33. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, et al. (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48: 1753-1760.
34. Liu S, Ansari IH, Das SC, Pattnaik AK, (2006) Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. J Gen Virol 87: 323-327.
35. Ge D, Fellay J, Thompson A, Simon J, Shianna K, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nat Genet 461: 399-401.
36. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
37. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
38. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 6: e21854.
39. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, et al. (2011) An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS ONE 6: e20904.
40. Cyr DD, Lucas JE, Thompson JW, Patel K, Clark PJ, et al. (2011) Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. PLoS ONE 6: e21854.
41. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, et al. (2010) Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138: 2307-2314.
42. Takagaki K, Arai H, Takayama K, (2010) Creation of a tablet database containing several active ingredients and prediction of their pharmaceutical characteristics based on ensemble artificial neural networks. J Pharm Sci 99: 4201-4214.